Peptomyc focuses on the development of a new generation of cell-penetrating peptides targeting the Myconcoprotein for cancer treatment.
Business Model:
Revenue: $0
Employees: 11-50
Address:
City: Barcelona
State: Catalonia
Zip:
Country: Spain
Peptomyc is a company focused on the development of a new generation of cell-penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years. Currently, cancer incidence in the world exceeds 14 million cases per year and results in 8 million deaths annually. Moreover, such numbers are forecast to rise by 75% over the next 20 years (World Cancer Report. International Agency for Research on Cancer 2014). At the moment, standard therapies include surgery, radiotherapy, chemotherapy, and, in a restricted subset of cancers, precision medicine. Unfortunately, very often these therapies fail, due to the development of resistance. Peptomyc has adopted a different strategy based on the inhibition of the oncoprotein Myc, which is found deregulated in the majority of human cancers. Myc holds a non-redundant function in cancer around which tumors cannot evolve, hence targeting Myc is the most promising therapeutic opportunity to date. Although Myc plays a central role in cancer there is currently no Myc inhibitor in the market.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 9/2017 | Series A | 1 | $5M |
Alta Life Sciences Alta Life Sciences |
7/2019 | Grant | 1 | $2.5M |
Horizon 2020 Horizon 2020 |
12/2020 | Venture Round | 4 | $13.9M |
Alta Life Sciences Aurora Science Centre for the Development of Industrial Technology (CDTI) Healthequity Alta Life Sciences Aurora Science Centre for the Development of Industrial Technology (CDTI) Healthequity |
4/2016 | Seed Round | 1 | $1.1M |
Healthequity Healthequity |
1/2016 | Seed Round | 1 | $54.3k |
EASME - EU Executive Agency for SMEs |
11/2016 | Grant | 2 | $900.5k |
European Commission Ministerio de Economia y Competitividad European Commission Ministerio de Economia y Competitividad |
5/2017 | Grant | 2 | $230.8k |
Ministerio de Economia y Competitividad Neotec Capital Riesgo Ministerio de Economia y Competitividad Neotec Capital Riesgo |
1/2022 | Venture Round | 3 | $3.3M |
Alta Life Sciences CDTI Healthequity Alta Life Sciences CDTI Healthequity |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|